Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Price Waterloo: China's New Bidding Process Hits MNCs Hard

Executive Summary

China's new so-called “4+7” drug bidding pilot scheme, already expected to be a killer for some companies, has cut prices by as much as 90%, leaving all but two multinationals to bid successfully and accept the revised levels. The big reductions could also lead to further price erosion for the winning products.

You may also be interested in...



Upjohn/Mylan: Will "Potential Moderate Growth" Lure Investors?

The combined company will have pro forma 2020 revenues of $19bn to $20bn, generate $1bn in synergies by 2023 and be led by Upjohn CEO Michael Goettler. Mylan's longtime CEO Heather Bresch will depart.

GSK Divests China Suzhou Site, Antiviral Rights To Fosun

GSK becomes latest pharma multinational to offload assets in China as competition and pricing pressure continue to mount.

How To Deliver Your China Growth Story: Trends To Watch

Caught between a grueling centralized bidding process and now potentially in trade war crossfire, foreign pharma firms have a lot on their plates in China. To succeed in this highly uncertain environment, observers point to the need to pursue excellence in multiple areas: product launches, medical coverage, the broad market and digital health.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel